PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Hidalgo, Manuel
TI  - MPACT Trial: SPARC Not Predictive or Prognostic in Pancreatic Cancer
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 11--11
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/11.short
4100  - http://mdc.sagepub.com/content/14/22/11.full
AB  - Secreted protein acidic and rich in cysteine (SPARC) protein expression levels were not associated with overall survival (OS) or progression-free survival (PFS) in patients with metastatic pancreatic cancer from the Phase 3 Study of ABI-007 (Albumin-Bound Paclitaxel) plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas trial [MPACT; Hidalgo M et al. Ann Oncol 2014 (abstr O-0003)]. This article presents data from a subanalysis of the MPACT trial.